AN OVERVIEW OF THE RHEUMATOLOGY OUTPATIENT CLINIC VISITS IN THE FIRST 16 MONTHS OF THE COVID-19 PANDEMIC: SINGLE-CENTRE EXPERIENCE

Year 2023, Volume: 32 Issue: 1, 106 - 112, 03.04.2023

Hüseyin Kaplan , Gizem Cengiz , Senem Şaş , Emre Şenköy

https://doi.org/10.34108/eujhs.1174356

Abstract

The aim of this study is to present a general picture of patients who applied to the rheumatology outpatient clinic in the first 16 months of the COVID-19pandemic. Patients who applied to the rheumatology outpatient clinic between March 2020 and August 2021 were included in the study. Patients’ clinical and demographic characteristics, the received drug treatments at their last admissions, and the outpatient clinic visits of patients within the specified 16-month period were evaluated retrospectively. A total of 869 patients were included, and their mean age was 48.51 ± 12.84 years; of these, 658 (75.71%) were female and 211 (24.29%) were male. The most common disease diagnosis was rheumatoid arthritis (29.57%). The average number of hospital visits in 2021 was significantly higher than in 2020. Also, patients who received both biological disease-modifying antirheumatic drugs (bDMARDs) and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)/immunosuppressives had a significantly higher number of admissions than those who did not (for all, p<0.05). The patients were divided into two groups based on their age as over and under 65 years of age, the number of outpatient clinic admissions was similar between the groups (p=0.620).We determined that the year of admission, gender, and the drugs used had significant effects on the number of applications during this period. These and other effects of the pandemic on rheumatic diseases should be demonstrated in multicenter prospective studies.

Keywords

COVID-19, outpatient clinic, rheumatology

Supporting Institution

None

Project Number

None

Thanks

None

COVID-19 PANDEMİSİNİN İLK 16 AYINDA ROMATOLOJİ POLİKLİNİK VİZİTLERİNE GENEL BİR BAKIŞ: TEK MERKEZ DENEYİMİ

Abstract

Bu çalışmanın amacı, COVID-19 pandemisinin ilk 16 ayında romatoloji polikliniğine başvuran hastaların genel bir resmini sunmaktır. Mart 2020-Ağustos 2021 tarihleri arasında romatoloji polikliniğine başvuran hastalar çalışmaya dahil edildi. Hastaların klinik ve demografik özellikleri, son başvurularında kullandıkları ilaç tedavileri ve belirlenen 16 aylık süre içerisinde poliklinik ziyaretleri retrospektif olarak değerlendirildi. Toplam 869 hasta dahil edildi ve hastaların ortalama yaşları 48.51 ± 12.84, 658'i (%75.71) kadın, 211'i (%24.29) erkekti. En sık görülen hastalık tanısı romatoid artrit (%29.57) idi.2021'deki ortalama hastane ziyareti sayısı 2020'den istatistiksel anlamlı olarak daha yüksekti. Ayrıca, hem biyolojik hastalık modifiye edici antiromatizmal ilaçlar (bDMARD'lar) hem de konvansiyonel sentetik hastalık modifiye edici antiromatizmal ilaçlar (csDMARD'lar)/immünosupresifler alan hastalar almayanlara göre daha yüksek başvuru sayısına sahipti (tümü için, p<0.05). Hastalar yaşlarına göre 65 yaş üstü ve altı olmak üzere iki gruba ayrıldığında poliklinik başvuru sayıları gruplar arasında benzerdi (p=0.620).Bu dönemde başvuru sayıları üzerine başvuru yılı, cinsiyet ve kullanılan ilaçların önemli etkileri olduğunu belirledik. Pandeminin romatizmal hastalıklar üzerindeki bu ve diğer etkileri çok merkezli prospektif çalışmalarla gösterilmelidir.

Keywords

COVID-19, poliklinik, romatoloji

Project Number

None

References

• Tezcan M, Mercan R. COVID-19 from rheumatology perspective. Nam Kem Med J 2020;557-563.
• Cankurtaran D, Tezel N. Evaluation of admission diagnoses of the patients admitted to the physical rehabilitation and medicine outpatient clinic at COVID-19 pandemic. J PMR Sci 2021;24(1):27-32.
• Yukselmis O. The steroid use in patients with rheumatic disease and COVID 19 infection. IAAOJ Health Sciences 2021;7(2):49-55.
• Caglar Yagcı H, Bagcıer F. Physical therapy and rehabilitation services after COVID-19. In: Ayhan FF, Kabayel DD, editors. COVID19 Pandemisi ve Fiziksel Tıp ve Rehabilitasyon. 1st ed. Ankara: Türkiye Klinikleri; 2020;ss 94-98.
• Avanoglu Guler A, Ozturk MA. COVID-19 in chronic diseases. GMJ 2020;31:266-270.
• Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis. Aging Dis 2020;11(3):668-678.
• Ahmed S, Gasparyan AY, Zimba O. Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int 2021;41(2):243-256.
• Akkoc N. Rheumatology patients pay the price for the flawed clinical trials on the treatment of COVID-19. RAED Journal 2020;12(3):88-95.
• Bilgin E. An overview of the recommendations of international rheumatology socities for the management of patients with rheumatic diseases during COVID-19 pandemic. In: Apraş Bilgin Ş, editor. COVID-19 Pandemisi ve Romatolojik Hastalıklar. 1st ed. Ankara: Türkiye Klinikleri; 2020;ss 61-64.
• Guler S, Topuz I, Ulusoy F. The experiences of family health center workers in the COVID-19 pandemic. Journal of Public Health Nursing 2020;2(3):143-151.
• Zagra L, Faraldi M, Pregliasco F, et al. Changes of clinical activities in an orthopaedic institute in North Italy during the spread of COVID-19 pandemic: a seven-week observational analysis. Int Orthop 2020;44(8):1591-1598.
• Fersia O, Bryant S, Nicholson R, et al. The impact of the COVID-19 pandemic on cardiology services. Open Heart 2020;7(2):e001359.
• Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009;11(3):1-16.
• Jokar M, Jokar M. Prevalence of inflammatory rheumatic diseases in a rheumatologic outpatient clinic: analysis of 12626 cases. Rheum Res 2018;3(1):21-27.
• Cakır N, Pamuk ON, Dervis E, et al. The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol Int 2012;32(4):895-908.
• Ziade N, El Khoury B, Zoghbi M, et al. Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: the COMORD study. Sci Rep 2020;10(1):1-10.
• Esatoglu SN, Tascilar K, Babaoglu H, et al. COVID-19 among patients with inflammatory rheumatic diseases. Front Immunol 2021;12:651715.
• Guler AA. Rheumatoid arthritis and comorbidities. In: Ateş A, editor. Romatoid Artrit. 1st ed. Ankara: Türkiye Klinikleri; 2020;ss 75-79.
• Altintas M, Ozata M. Assessment of the restrictions enforced and the steps taken for going back to normal during the COVID-19 pandemic process in Turkey. Kırşehir Ahi Evran Üniversitesi Sağlık Bilimleri Dergisi 2021;1(3):172-185.
• Ogulcan M. People's view of COVID-19 vaccine in Turkey. Dicle Med J. 2021;48(3):583-594.
• Basaga SM, Ture Z, Unuvar GK, et al. COVID-19 pandemic estimated end date in Turkey. Klinik Journal 2021;34(2):87-94.
• Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med 2007;120(11):936-939.
• Spagnolo P, Cordier J-F, Cottin V: Connective tissue diseases, multimorbidity and the ageing lung. Eur Respir J 2016; 47(5):1535-1558.
• Uysal Y, Akpinar E. Illness perception and depression of type 2 diabetic patients. Cukurova Med J 2013;38(1):31-40.
• Dogru A. Anti-cytokine treatments in COVID-19 disease: IL-6 receptor inhibitor (tocilizumab) and IL-1 receptor antagonist (anakinra). Med J SDU 2021; 1(1):163-166.
• Ziadé N, Hmamouchi I, El Kibbi L, et al. The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. Clin Rheumatol 2020; 39(11):3205-3213.
• Romão VC, Cordeiro I, Macieira C, et al. Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view. RMD open. 2020;6(2):e001314.
• Singh BSM, Chuah SL, Cheong YK, Wan SA, Teh CL. Impact of lockdown on rheumatology outpatient care in the age of COVID-19. Ann Rheum Dis 2020; annrheumdis-2020-218484.
• Pineda-Sic RA, Galarza-Delgado DA, Serna-Peña G, et al. Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience. Ann Rheum Dis 2020; annrheumdis-2020-218198.
• Fragoulis GE, Evangelatos G, Arida A, et al. Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. Ann Rheum Dis 2020; annrheumdis-2020-217935.
• Michaud K, Wipfler K, Shaw Y, et al. Experiences of patients with rheumatic diseases in the United States during early days of the COVID‐19 pandemic. ACR Open Rheumatol 2020; 2(6):335-43.